Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00622193
Official study title

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Study summary

The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedanamorelin HCl and anamorelin HCl

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 14, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?33 U.S. locations

Locations may change over time.

Who runs it?Helsinn Therapeutics (U.S.), Inc

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Helsinn Therapeutics (U.S.), Inc
Interventions being studied
Drug: anamorelin HCl; Drug: anamorelin HCl; Drug: placebo
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • stage IIIB or IV NSCLC
  • eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab
Reasons someone may not be able to joinExclusion criteria
  • mixed large and small cell histologies for lung cancer
  • significant obesity, BMI \> 30

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Arkansas for Medical SciencesLittle Rock, Arkansas
  • Osler MedicalMelbourne, Florida
  • Augusta Oncology AssociatesAugusta, Georgia
  • South Georgia Medical CenterValdosta, Georgia
  • Investigative Clinical Research of IndianaIndianapolis, Indiana
  • John Hopkins UniversityBaltimore, Maryland
  • Massachusetts General HospitalBoston, Massachusetts
  • Dana Farber Cancer CenterBoston, Massachusetts
  • Caritas St. Elizabeth's Medical CenterBoston, Massachusetts
  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • The West ClinicCorinth, Mississippi
  • The West ClinicSouthaven, Mississippi

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 14, 2017. Always confirm current availability with the study team.

View original record ↗